Company Name	Mesoblast Limited
Registered Office	(Effective 23 June 2014) Level 38 55 Collins Street Melbourne VIC 3000 Australia Tel: (61) 3 9639 6036 Fax: (61) 3 9639 6030
Principal Place of Business	(Effective 23 June 2014) Level 38 55 Collins Street Melbourne VIC 3000 Australia Tel: (61) 3 9639 6036 Fax: (61) 3 9639 6030
Other Offices	US Office Level 3 505 Fifth Avenue New York, NY 10017 United States of America Tel: (1) 212 880 2060 Fax: (1) 212 880 2061 Asia Office 20 Biopolos Way #05-01 Centros Biopreneur 3 Singapore 138668 Tel: (65) 6570 0635 Fax: (65) 6570 0176
Sector	Life Science / Biotechnology / Medical / Pharmaceutical / Regenerative Medicines
GICS Industry Group	Pharmaceuticals / Biotechnology & Life Sciences
Principal Activities	Mesoblast is a world leader in innovative cell-based medicines. It has leveraged its proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells to establish one of the most advanced cellular medicines portfolio in the industry
Internet Homepage Address (URL)	http://www.mesoblast.com
Email Address	info@mesoblast.com
Financial Year End	June 30
Board of Directors	Brian Jamieson (Non-Executive Chairman) William M. Burns (Vice Chairman) (Appointed on 1 September 2016) Silviu Itescu (Chief Executive Officer and Executive Director) Donal O'Dwyer (Non-Executive Director) Eric A. Rose (Non-Executive Director) (Appointed on 17 April 2013) Michael Spooner (Non-Executive Director) Ben-Zion Weiner (Non-Executive Director) (Appointed on 10 May 2012) Charlie Harrison (Appointed on 1 September 2014)
Management Team	Silviu Itescu (Chief Executive Officer & Managing Director) Paul Hodgkinson (Chief Financial Officer) (Appointed on 25 August 2014) Roger D. Brown (Spinal Orthopedic Disorders) Peter Howard (Corporate Executive & General Counsel) John D. McMannis (Manufacturing) Julie Meldrum (Global Corporate Communications) Michael Schuster (Pharma Partnering) Karen Segal (Diabetes and Metabolic Diseases) Paul J. Simmons (Research and New Product Development) Donna Skerrett (Chief Medical Officer) Geraldine Storton (Head of Regulatory Affairs & Quality Management) Eric Strati (Commercial) Jonathan R. Symonds (Corporate Finance & Strategy) (Appointed on 11 March 2014)
Company Secretary	Charlie Harrison (Appointed on 1 September 2014)
Investor Relations Contact	Julie Meldrum (Global Head of Corporate Communications) Schond Greenway (Investor Relations)
Principal Bankers	National Australia Bank Ltd 221 Drummond Street Carlton VIC 3053
Auditors	PricewaterhouseCoopers Freshwater Place Level 19, Southbank Boulevard Southbank, VIC 3006 Australia Tel: (61) 3 8603 1000 Fax: (61) 3 8603 1999
Share Registry	Link Market Services Limited Tower 4, 727 Collins Street Docklands Melbourne, VIC 3008 Australia Tel: (61) 1300 554 474 Fax: (61) 2 9287 0303 Website: www.linkmarketservices.com.au
ASX Stock Code	MSB
Listing Date	16 December 2004
S&P/ASX 300 Index	Included in S&P/ASX 300 Index on 17 September 2016
Issued Capital	381,363,137 ordinary share (no par value) (as of 30 June 2016)
Issued Shares in FY2015	~15.4 million (including 4.5% equity stake to Celgene Corporation) (as of 23 October 2015)
Market Capitalisation	A$412 million (as of 30 June 2016) A$1.15 billion (as of 21 October 2015) $1,267million (as of 30 June 2015) $1.89 billion (as of 25 February 2014) $1.95 billion (as of 14 November 2013) $1.78 billion (as of 28 August 2013) $1,647 million (at $5.74 on 28 November 2012) ($1,841 million at $6.44 on 21 August 2012) $2,100 million as of 23 March 2012) (US$1,870 million as of 12 January 2012) (A$2,300 million as of 9 November 2011) (A$2,008 million as of 24 August 2011) (A$1,575 million as of 9 February 2011) (A$455 million as of 12 May 2010) (A$282 million as of 13 January 2010)
MSB Ownership	. Institution / Sophisticated Investors - 35% . Management - 30% . Strategic Investors - 23% . Retail - 12% (as of 21 December 2015)
Cash and Cash Equivalents	US$33,902,000 (as of 31 December 2016) US$60,355,000 (as of 30 September 2016) US$80,937,000 (as of 30 June 2016) US$99,929,000 (as of 31 March 2016) US$121 million (as of 31 December 2015) US$77,761,000 (as of 30 September 2015) A$144,142,000 (as of 30 June 2015) A$124,046,000 (as of 31 March 2015) A$149,195,000 (as of 31 December 2014) A$196,394,000 (as of 30 June 2014) A$241,448,000 (as of 31 March 2014)
Staff	‧ Total - 108 (2015: 115) ‧ Australia - 27 ‧ US - 71 ‧ Singapore - 9 ‧ Switzerland - 1 (as of 30 June 2016)
Nasdaq Listing	Listed on Nasdaq on 13 November 2015 under the symbol MESO
ACN	109 431 870
ABN	68 109 431 870